logo

For the Inventor, By the Inventor

Saint-Sixt, France

Olivier Leger

This inventor holds 21 USPTO granted patents and 4 published patent applications and 3 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Merck Patent Gmbh, Pierre Fabre Medicament, Calypso Biotech Sa. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olivier Leger. Retrieved from https://idiyas.com/inventor/olivier-leger-pgb0zlce

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 71.4

 

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 155(Granted Patents)


Location History:

  • Annemasse, FR (2007 - 2014)
  • Saint Sixt, FR (2012 - 2024)

Company Filing History:

goldMedal8 out of 3,025 
 
Merck Patent Gmbh
 patents
silverMedal6 out of 269 
 
Pierre Fabre Medicament
 patents
bronzeMedal3 out of 3 
 
Calypso Biotech Sa
 patents
4. 2 out of 5 
 
Biomunex Pharmaceuticals
 patents
5. 2 out of 145 
 
Merck Serono S. a.
 patents
6. 1 out of 139 
 
Ares Trading S.a.
 patents
where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-PD-L1
Monoclonal Antibodies
Polypeptides
IL-17A
IL-15
CD38
MMP9
GM-CSF
Hybrid Receptors
Therapeutics
21 patents (USPTO):Explore Patents
1. 11884724 - Anti-PD-L1 antibodies and uses thereof (2024-01-30),
2. 11773159 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2023-10-03),
3. 11560437 - Stable multispecific antibodies (2023-01-24),
4. 11505616 - Binding molecules to CD38 and PD-L1 (2022-11-22),
5. 11130806 - Antibodies to IL-15 and uses thereof (2021-09-28),
6. 10829552 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2020-11-10),
7. 10759856 - Anti-PD-L1 antibodies and uses thereof (2020-09-01),
8. 10487147 - Anti-PD-L1 antibodies and uses thereof (2019-11-26),
9. 10364296 - Antibodies specific for MMP9 (2019-07-30),
10. 10301384 - Antibodies to IL-15 (2019-05-28),
11. 10017568 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same (2018-07-10),
12. 9624298 - Anti-PD-L1 antibodies and uses thereof (2017-04-18),
13. 9567398 - Antibody with specificity for GM-CSF (II) (2017-02-14),
14. 9567397 - Antibody with specificity for GM-CSF (I) (2017-02-14),
15. 9534054 - Monoclonal antibody directed against CXCR5 (2017-01-03),

Title: The Innovative Journey of Olivier Leger

Introduction: Olivier Leger, a talented inventor hailing from Saint-Sixt, France, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Olivier Leger's latest patents focus on renewable energy solutions, including a revolutionary wind turbine design that maximizes energy production while minimizing environmental impact.

Career Highlights: With a background in mechanical engineering, Olivier Leger has spent over two decades developing innovative solutions for various industries, ranging from sustainable energy to transportation.

Collaborations: Throughout his career, Olivier Leger has collaborated with leading research institutions and universities to further his research and bring his inventions to life. His partnerships have led to groundbreaking discoveries and advancements in the field of technology.

Conclusion: Olivier Leger's passion for innovation and dedication to creating a sustainable future have solidified his position as a respected inventor in the global tech community. His contributions continue to inspire and drive progress in the ever-evolving world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…